We use cookies for a better user experience. Read our Privacy Policy
I Agree
Gynecology Drugs Market Insights, 2018-2026
Gynecological diseases represent a collective term given to different medical conditions specific to the female reproductive system. Thus, gynecological diseases include conditions affecting the uterus, ovaries and their appendages. Gynecology drugs are the therapeutics utilized for the treatment of various gynecological diseases and symptoms. The global gynecological devices market was valued at US$ 53,376.96 Mn in 2017. It is expected to expand at a CAGR of 5.5% from 2018 to 2026.
In the last decade, the adoption of gynecology drugs has increased owing to the rise in prevalence of gynecological diseases. Change in lifestyle of the global female population has gradually enhanced their healthcare requirements. Consistent rise in awareness about health and well-being has led to an increase in the demand for better gynecological treatments. Sensing this opportunity, various drug manufacturers worldwide have devised more innovative gynecology therapeutics that have better efficacy and minimum side-effects. Furthermore, rising geriatric female population and economic growth are the key factors that are likely to offer lucrative opportunity to the gynecology drugs market.
The global gynecology drugs market has been segmented based on therapeutics, indication, distribution channel, and region. Furthermore, in terms of therapeutics, the market has been divided into hormonal therapy and non-hormonal therapy. The non-hormonal therapy segment is likely to account for a leading share of the global market during the forecast period owing to the effectiveness of the products, rise in adoption of these products, and new product development. Decreasing use of hormonal products due to the risk of breast cancer has boosted the demand for non-hormonal pharmaceutical products. In terms of indication, the market has been classified into gynecology cancers, endometriosis, female infertility, menopausal disorder, gynecology infections, polycystic ovary syndrome, contraception (birth control), and others. In terms of distribution channel, the market has been segregated into hospital pharmacies, retail pharmacies, and online pharmacies. The online pharmacies segment is expected to expand at a significant CAGR during forecast period, owing to the convenience of using online pharmacy and rise in number of internet users.
In terms of region, the global gynecology drugs market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounted for a major share of the global market in 2017, primarily due to high investments made in cutting-edge drug research, resulting in new, sophisticated treatments with specific mechanism of action; rising emphasis on cancer care, and concentration of some of the world’s major pharmaceutical and biotechnology organizations in the region. The market in Asia Pacific is anticipated to be highly attractive in the near future due to the existence of a large patient pool, increasing awareness coupled with increase in government funding, and developmental initiatives in healthcare facilities in the region. Moreover, low cost of manufacturing in China and India has resulted in the rise in production facilities, attracting key players to the region from across the world. BRICS (Brazil, Russia, India, China, and South Africa) countries are among the fastest-growing economies in the world. According to Siemens Healthineers, health care expenditure in emerging economies increased 11% from 1995 to 2012, which is expected to reach 33% by 2022. Rising population in emerging countries is likely to lead to increased demand for pharmaceutical and biopharmaceutical products in the near future.
Key players operating in the global gynecology drugs market include Eli Lilly and Company, Pfizer, Inc., Merck & Co., Inc, Amgen Inc., AstraZeneca, F. Hoffmann-La Roche Ltd., Allergan Plc, and Bayer AG. These companies have diverse product offerings and extensive distribution systems across the world. Moreover, entry of small players, especially in emerging markets of Asia, is being witnessed. However, stringent regulatory framework and high-quality standards set by market leaders are anticipated to restrain the penetration of new entrants in the market.
Gynecology Drugs Market - Snapshot
In the last few years, the growth of gynecology drugs has expanded considerably because of the ascent in prevalence of gynecological diseases. Change in way of life of the worldwide female populace has gradually improved their demand for high end medical care necessities. Predictable ascent in mindfulness about wellbeing and prosperity has prompted an expansion in the interest for better gynecological medicines. Detecting this chance, different medication makers worldwide have formulated more imaginative gynecology therapeutics that have better adequacy and least results. Besides, rising geriatric female populace and monetary development are the key factors that are probably going to offer rewarding freedom to the gynecology drugs market.
Gynecologic problems influence the female reproductive system. The most common symptoms of gynecologic problems incorporate pelvic agony, vaginal tingling, vaginal release, strange vaginal dying, and bosom torment and protuberances. The importance and seriousness of these symptoms regularly rely upon age, as these symptoms might be identified with hormonal changes that happen with maturing.
Among other noticeable gynecological diseases, sexually sent illness (STD) is the most common and basic – the most common STD among women is pelvic provocative infection. In the U.S. alone, more than 1,000,000 women suffer from this issue in the course of their life, trailed by chlamydia – a sexually communicated contamination of the vagina, which, whenever left untreated, forms into pelvic incendiary illness. Gynecological problems could possibly be identified with the feminine cycle, which noticeably incorporate feminine issues and endometriosis (strangely found patches of tissue that is ordinarily found distinctly in the covering of the uterus). Moreover, gynecological cancers are additionally common among women all throughout the planet. Endometrial disease and ovarian malignant growth are profoundly common among women. Subsequently, expansion in the prevalence of the conditions referenced above, are probably going to build the take-up of gynecology drugs.
The global gynecology drugs market has been segmented as given below:
|
Therapeutics |
|
|
Indication |
|
|
Distribution Channel |
|
|
Region |
|
Interested in this report?
Get a FREE Brochure now!
*Get Brochure Report (PDF) sent to your email within minutes
The global gynecology drugs market was worth US$ 53.376.96 Mn and is projected to reach a value of US$ 85,833.02 Mn by the end of 2026
Gynecology drugs market is anticipated to grow at a CAGR of 5.5% during the forecast period
North america accounted for a major share of the global gynecology drugs market
Incidence of menopausal vasomotor symptoms has risen significantly in the last few years, which in turn drives the global gynecology drugs market
Key players in the global gynecology drugs market include Eli Lilly and Company, Pfizer, Inc., Merck & Co., Inc, Amgen Inc., AstraZeneca, F. Hoffmann-La Roche Ltd., Allergan Plc, and Bayer AG
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Assumptions and Acronyms Used
2.2. Research Methodology
3. Executive Summary
3.1. Global Gynecology Drugs Market: Market Snapshot
4. Market Overview
4.1. Global Gynecology Drugs Market: Product Overview
4.2. Global Gynecology Drugs Market: Key Industry Developments
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Gynecology Drugs Market Revenue Projections, 2016–2026
4.5. Porter’s Five Forces Analysis
4.6. Global Gynecology Drugs Market Outlook
5. Market Outlook
5.1. Regulatory Scenario
5.2. Disease Prevalence
5.3. Pipeline Analysis
6. Global Gynecology Drugs Market Analysis, by Therapeutics
6.1. Key Findings
6.2. Introduction
6.3. Global Gynecology Drugs Market Value Share, by Therapeutics
6.4. Global Gynecology Drugs Market Value Forecast, by Therapeutics
6.4.1. Hormonal Therapy
6.4.1.1. Estrogen Therapy
6.4.1.2. Progestin Therapy
6.4.1.3. Combination Therapy
6.4.1.4. Thyroid Replacement Therapy
6.4.1.5. Parathyroid Hormone Therapy
6.4.1.6. Others
6.4.2. Non-hormonal Therapy
6.4.2.1. Anti-Infective Agents
6.4.2.2. Anti-neoplastic Agents
6.4.2.3. Anti-inflammatory Agents
6.4.2.4. Others
6.5. Global Gynecology Drugs Market Analysis, by Therapeutics
6.6. Global Gynecology Drugs Market Attractiveness Analysis, by Therapeutics
7. Global Gynecology Drugs Market Analysis, by Indication
7.1. Key Findings
7.2. Introduction
7.3. Global Gynecology Drugs Market Value Share, by Indication
7.4. Global Gynecology Drugs Market Value Forecast, by Indication
7.4.1.1. Gynecology Cancers
7.4.1.2. Endometriosis
7.4.1.3. Female Infertility
7.4.1.4. Menopausal Disorder
7.4.1.5. Gynecology Infections
7.4.1.6. Polycystic Ovary Syndrome
7.4.1.7. Contraception (Birth Control)
7.4.1.8. Others
7.5. Global Gynecology Drugs Market Analysis, by Indication
7.6. Global Gynecology Drugs Market Attractiveness Analysis, by Indication
8. Global Gynecology Drugs Market Analysis, by Distribution Channel
8.1. Key Findings
8.2. Introduction
8.3. Global Gynecology Drugs Market Value Share, by Distribution Channel
8.4. Global Gynecology Drugs Market Value Forecast, by Distribution Channel
8.4.1. Hospital Pharmacies
8.4.2. Retail Pharmacies
8.4.3. Online Pharmacies
8.5. Global Gynecology Drugs Market Analysis, by Distribution Channel
8.6. Global Gynecology Drugs Market Attractiveness Analysis, by Distribution Channel
9. Global Gynecology Drugs Market Analysis, by Region
9.1. Global Gynecology Drugs Market Scenario, by Country
9.2. Global Gynecology Drugs Market Value Share, by Region
9.3. Global Gynecology Drugs Market Value Forecast, by Region
9.3.1. North America
9.3.2. Europe
9.3.3. Asia Pacific
9.3.4. Latin America
9.3.5. Middle East & Africa
9.4. Global Gynecology Drugs Market Attractiveness Analysis, by Region
10. North America Gynecology Drugs Market Analysis
10.1. Key Findings
10.2. North America Gynecology Drugs Market Overview
10.3. North America Gynecology Drugs Market Value Share, by Country
10.4. North America Gynecology Drugs Market Forecast, by Country
10.4.1. U.S.
10.4.2. Canada
10.5. North America Gynecology Drugs Market Value Share Analysis, by Therapeutics
10.6. North America Gynecology Drugs Market Forecast, by Therapeutics
10.6.1. Hormonal Therapy
10.6.1.1. Estrogen Therapy
10.6.1.2. Progestin Therapy
10.6.1.3. Combination Therapy
10.6.1.4. Thyroid Replacement Therapy
10.6.1.5. Parathyroid Hormone Therapy
10.6.1.6. Others
10.6.2. Non-hormonal Therapy
10.6.2.1. Anti-Infective Agents
10.6.2.2. Anti-neoplastic Agents
10.6.2.3. Anti-inflammatory Agents
10.6.2.4. Others
10.7. North America Gynecology Drugs Market Value Share Analysis, by Indication
10.8. North America Gynecology Drugs Market Forecast, by Indication
10.8.1. Gynecology Cancers
10.8.2. Endometriosis
10.8.3. Female Infertility
10.8.4. Menopausal Disorder
10.8.5. Gynecology Infections
10.8.6. Polycystic Ovary Syndrome
10.8.7. Contraception (Birth Control)
10.8.8. Others
10.9. North America Gynecology Drugs Market Value Share Analysis, by Distribution Channel
10.10. North America Gynecology Drugs Market Forecast, by Distribution Channel
10.10.1. Hospital Pharmacies
10.10.2. Retail Pharmacies
10.10.3. Online Pharmacies
10.11. North America Gynecology Drugs Market Attractiveness Analysis
11. Europe Gynecology Drugs Market Analysis
11.1. Key Findings
11.2. Europe Gynecology Drugs Market Overview
11.3. Europe Gynecology Drugs Market Value Share, by Country/Sub-region
11.4. Europe Gynecology Drugs Market Forecast, by Country/Sub-region
11.4.1. UK
11.4.2. Germany
11.4.3. France
11.4.4. Italy
11.4.5. Spain
11.4.6. Rest of Europe
11.5. Europe Gynecology Drugs Market Value Share Analysis, by Therapeutics
11.6. Europe Gynecology Drugs Market Forecast, by Therapeutics
11.6.1. Hormonal Therapy
11.6.1.1. Estrogen Therapy
11.6.1.2. Progestin Therapy
11.6.1.3. Combination Therapy
11.6.1.4. Thyroid Replacement Therapy
11.6.1.5. Parathyroid Hormone Therapy
11.6.1.6. Others
11.6.2. Non-hormonal Therapy
11.6.2.1. Anti-Infective Agents
11.6.2.2. Anti-neoplastic Agents
11.6.2.3. Anti-inflammatory Agents
11.6.2.4. Others
11.7. Europe Gynecology Drugs Market Value Share Analysis, by Indication
11.8. Europe Gynecology Drugs Market Forecast, by Indication
11.8.1. Gynecology Cancers
11.8.2. Endometriosis
11.8.3. Female Infertility
11.8.4. Menopausal Disorder
11.8.5. Gynecology Infections
11.8.6. Polycystic Ovary Syndrome
11.8.7. Contraception (Birth Control)
11.8.8. Others
11.9. Europe Gynecology Drugs Market Value Share Analysis, by Distribution Channel
11.10. Europe Gynecology Drugs Market Forecast, by Distribution Channel
11.10.1. Hospital Pharmacies
11.10.2. Retail Pharmacies
11.10.3. Online Pharmacies
11.11. Europe Gynecology Drugs Market Attractiveness Analysis
12. Asia Pacific Gynecology Drugs Market Analysis
12.1. Key Findings
12.2. Asia Pacific Gynecology Drugs Market Overview
12.3. Asia Pacific Gynecology Drugs Market Value Share, by Country/Sub-region
12.4. Asia Pacific Gynecology Drugs Market Forecast, by Country/Sub-region
12.4.1. China
12.4.2. Japan
12.4.3. India
12.4.4. Australia & New Zealand
12.4.5. Rest of Asia Pacific
12.5. Asia Pacific Gynecology Drugs Market Value Share Analysis, by Therapeutics
12.6. Asia Pacific Gynecology Drugs Market Forecast, by Therapeutics
12.6.1. Hormonal Therapy
12.6.1.1. Estrogen Therapy
12.6.1.2. Progestin Therapy
12.6.1.3. Combination Therapy
12.6.1.4. Thyroid Replacement Therapy
12.6.1.5. Parathyroid Hormone Therapy
12.6.1.6. Others
12.6.2. Non-hormonal Therapy
12.6.2.1. Anti-Infective Agents
12.6.2.2. Anti-neoplastic Agents
12.6.2.3. Anti-inflammatory Agents
12.6.2.4. Others
12.7. Asia Pacific Gynecology Drugs Market Value Share Analysis, by Indication
12.8. Asia Pacific Gynecology Drugs Market Forecast, by Indication
12.8.1. Gynecology Cancers
12.8.2. Endometriosis
12.8.3. Female Infertility
12.8.4. Menopausal Disorder
12.8.5. Gynecology Infections
12.8.6. Polycystic Ovary Syndrome
12.8.7. Contraception (Birth Control)
12.8.8. Others
12.9. Asia Pacific Gynecology Drugs Market Value Share Analysis, by Distribution Channel
12.10. Asia Pacific Gynecology Drugs Market Forecast, by Distribution Channel
12.10.1. Hospital Pharmacies
12.10.2. Retail Pharmacies
12.10.3. Online Pharmacies
12.11. Asia Pacific Gynecology Drugs Market Attractiveness Analysis
13. Latin America Gynecology Drugs Market Analysis
13.1. Key Findings
13.2. Latin America Gynecology Drugs Market Overview
13.3. Latin America Gynecology Drugs Market Value Share, by Country/Sub-region
13.4. Latin America Gynecology Drugs Market Forecast, by Country/Sub-region
13.4.1. Brazil
13.4.2. Mexico
13.4.3. Rest of Latin America
13.5. Latin America Gynecology Drugs Market Value Share Analysis, by Therapeutics
13.6. Latin America Gynecology Drugs Market Forecast, by Therapeutics
13.6.1. Hormonal Therapy
13.6.1.1. Estrogen Therapy
13.6.1.2. Progestin Therapy
13.6.1.3. Combination Therapy
13.6.1.4. Thyroid Replacement Therapy
13.6.1.5. Parathyroid Hormone Therapy
13.6.1.6. Others
13.6.2. Non-hormonal Therapy
13.6.2.1. Anti-Infective Agents
13.6.2.2. Anti-neoplastic Agents
13.6.2.3. Anti-inflammatory Agents
13.6.2.4. Others
13.7. Latin America Gynecology Drugs Market Value Share Analysis, by Indication
13.8. Latin America Gynecology Drugs Market Forecast, by Indication
13.8.1. Gynecology Cancers
13.8.2. Endometriosis
13.8.3. Female Infertility
13.8.4. Menopausal Disorder
13.8.5. Gynecology Infections
13.8.6. Polycystic Ovary Syndrome
13.8.7. Contraception (Birth Control)
13.8.8. Others
13.9. Latin America Gynecology Drugs Market Value Share Analysis, by Distribution Channel
13.10. Latin America Gynecology Drugs Market Forecast, by Distribution Channel
13.10.1. Hospital Pharmacies
13.10.2. Retail Pharmacies
13.10.3. Online Pharmacies
13.11. Latin America Gynecology Drugs Market Attractiveness Analysis
14. Middle East & Africa Gynecology Drugs Market Analysis
14.1. Key Findings
14.2. Middle East & Africa Gynecology Drugs Market Overview
14.3. Middle East & Africa Gynecology Drugs Market Value Share, by Country/Sub-region
14.4. Middle East & Africa Gynecology Drugs Market Forecast, by Country/Sub-region
14.4.1. GCC
14.4.2. South Africa
14.4.3. Rest of MEA
14.5. Middle East & Africa Gynecology Drugs Market Value Share Analysis, by Therapeutics
14.6. Middle East & Africa Gynecology Drugs Market Forecast, by Therapeutics
14.6.1. Hormonal Therapy
14.6.1.1. Estrogen Therapy
14.6.1.2. Progestin Therapy
14.6.1.3. Combination Therapy
14.6.1.4. Thyroid Replacement Therapy
14.6.1.5. Parathyroid Hormone Therapy
14.6.1.6. Others
14.6.2. Non-hormonal Therapy
14.6.2.1. Anti-Infective Agents
14.6.2.2. Anti-neoplastic Agents
14.6.2.3. Anti-inflammatory Agents
14.6.2.4. Others
14.7. Middle East & Africa Gynecology Drugs Market Value Share Analysis, by Indication
14.8. Middle East & Africa Gynecology Drugs Market Forecast, by Indication
14.8.1. Gynecology Cancers
14.8.2. Endometriosis
14.8.3. Female Infertility
14.8.4. Menopausal Disorder
14.8.5. Gynecology Infections
14.8.6. Polycystic Ovary Syndrome
14.8.7. Contraception (Birth Control)
14.8.8. Others
14.9. Middle East & Africa Gynecology Drugs Market Value Share Analysis, by Distribution Channel
14.10. Middle East & Africa Gynecology Drugs Market Forecast, by Distribution Channel
14.10.1. Hospital Pharmacies
14.10.2. Retail Pharmacies
14.10.3. Online Pharmacies
14.11. Middle East & Africa Gynecology Drugs Market Attractiveness Analysis
15. Competition Landscape
15.1. Gynecology Drugs Market Share Analysis, by Company, 2017
15.2. Competition Matrix
15.3. Company Profiles
15.3.1. Allergan plc.
15.3.1.1. Company Details
15.3.1.2. Business Overview
15.3.1.3. Financial Overview
15.3.1.4. Strategic Overview
15.3.1.5. SWOT Analysis
15.3.2. Amgen Inc.
15.3.2.1. Company Details
15.3.2.2. Business Overview
15.3.2.3. Financial Overview
15.3.2.4. Strategic Overview
15.3.2.5. SWOT Analysis
15.3.3. Bayer AG
15.3.3.1. Company Details
15.3.3.2. Business Overview
15.3.3.3. Financial Overview
15.3.3.4. Strategic Overview
15.3.3.5. SWOT Analysis
15.3.4. Merck & Co., Inc.
15.3.4.1. Company Details
15.3.4.2. Business Overview
15.3.4.3. Financial Overview
15.3.4.4. Strategic Overview
15.3.4.5. SWOT Analysis
15.3.5. Pfizer Inc.
15.3.5.1. Company Details
15.3.5.2. Business Overview
15.3.5.3. Financial Overview
15.3.5.4. Strategic Overview
15.3.5.5. SWOT Analysis
15.3.6. Eli Lilly Company
15.3.6.1. Company Details
15.3.6.2. Business Overview
15.3.6.3. Financial Overview
15.3.6.4. Strategic Overview
15.3.6.5. SWOT Analysis
15.3.7. F. Hoffmann-La Roche Ltd.
15.3.7.1. Company Details
15.3.7.2. Business Overview
15.3.7.3. Financial Overview
15.3.7.4. Strategic Overview
15.3.7.5. SWOT Analysis
15.3.8. AstraZeneca
15.3.8.1. Company Details
15.3.8.2. Business Overview
15.3.8.3. Financial Overview
15.3.8.4. Strategic Overview
15.3.8.5. SWOT Analysis
List of Tables
Table 01: Global Gynecology Drugs Market Value (US$ Mn) Forecast, by Therapeutics, 2016–2026
Table 02: Global Gynecology Drugs Market Value (US$ Mn) Forecast, by Hormonal Therapy, 2016–2026
Table 03: Global Gynecology Drugs Market Value (US$ Mn) Forecast, by Non-Hormonal Therapy, 2016–2026
Table 04: Global Gynecology Drugs Market Value (US$ Mn) Forecast, by Indication, 2018–2026
Table 05: Global Gynecology Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 06: Global Gynecology Drugs Market Value (US$ Mn) Forecast, by Region, 2016–2026
Table 07: North America Gynecology Drugs Market Value (US$ Mn) Forecast, by Country, 2018–2026
Table 08: North America Gynecology Drugs Market Value (US$ Mn) Forecast, by Therapeutics, 2016–2026
Table 09: North America Gynecology Drugs Market Value (US$ Mn) Forecast, by Hormonal Therapy, 2016–2026
Table 10: North America Gynecology Drugs Market Value (US$ Mn) Forecast, by Non-Hormonal Therapy, 2016–2026
Table 11: North America Gynecology Drugs Market Value (US$ Mn) Forecast, by Indication, 2018–2026
Table 12: North America Gynecology Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 13: Europe Gynecology Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2026
Table 14: Europe Gynecology Drugs Market Value (US$ Mn) Forecast, by Therapeutics, 2016–2026
Table 15: Europe Gynecology Drugs Market Value (US$ Mn) Forecast, by Hormonal Therapy, 2016–2026
Table 16: Europe Gynecology Drugs Market Value (US$ Mn) Forecast, by Non-Hormonal Therapy, 2016–2026
Table 17: Europe Gynecology Drugs Market Value (US$ Mn) Forecast, by Indication, 2018–2026
Table 18: Europe Gynecology Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 19: Asia Pacific Gynecology Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2026
Table 20: Asia Pacific Gynecology Drugs Market Value (US$ Mn) Forecast, by Therapeutics, 2016–2026
Table 21: Asia Pacific Gynecology Drugs Market Value (US$ Mn) Forecast, by Hormonal Therapy, 2016–2026
Table 22: Asia Pacific Gynecology Drugs Market Value (US$ Mn) Forecast, by Non-hormonal Therapy, 2016–2026
Table 23: Asia Pacific Gynecology Drugs Market Value (US$ Mn) Forecast, by Indication, 2018–2026
Table 24: Asia Pacific Gynecology Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 25: Latin America Gynecology Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2026
Table 26: Latin America Gynecology Drugs Market Value (US$ Mn) Forecast, by Therapeutics, 2016–2026
Table 27: Latin America Gynecology Drugs Market Value (US$ Mn) Forecast, by Hormonal Therapy, 2016–2026
Table 28: Latin America Gynecology Drugs Market Value (US$ Mn) Forecast, by Non-hormonal Therapy, 2016–2026
Table 29: Latin America Gynecology Drugs Market Value (US$ Mn) Forecast, by Indication, 2018–2026
Table 30: Latin America Gynecology Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 31: Middle East & Africa Gynecology Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2026
Table 32: Middle East & Africa Gynecology Drugs Market Value (US$ Mn) Forecast, by Therapeutics, 2016–2026
Table 33: Middle East & Africa Gynecology Drugs Market Value (US$ Mn) Forecast, by Hormonal Therapy, 2016–2026
Table 34: Middle East & Africa Gynecology Drugs Market Value (US$ Mn) Forecast, by Non-hormonal Therapy, 2016–2026
Table 35: Middle East & Africa Gynecology Drugs Market Value (US$ Mn) Forecast, by Indication, 2018–2026
Table 36: Middle East & Africa Gynecology Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
List of Figures
Figure 01: Global Gynecology Drugs Market Revenue Projection (US$ Mn), 2016–2026
Figure 02: Global Gynecology Drugs Market Value Share, by Therapeutics, 2018
Figure 03: Global Gynecology Drugs Market Value Share, by Indication, 2018
Figure 04: Global Gynecology Drugs Market Value Share, by Region, 2018
Figure 05: Global Gynecology Drugs Market Value Share, by Distribution Channel, 2018
Figure 06: Global Gynecology Drugs Market Value Share Analysis, by Therapeutics, 2018 and 2026
Figure 07: Global Gynecology Drugs Market Value (US$ Mn) and Y-o-Y Growth, by Hormonal Therapy, 2016–2026
Figure 08: Global Gynecology Drugs Market Value (US$ Mn) and Y-o-Y Growth, by Non-Hormonal Therapy, 2016–2026
Figure 09: Global Gynecology Drugs Market Attractiveness, by Therapeutics, 2018–2026
Figure 10: Global Gynecology Drugs Market Value Share Analysis, by Indication, 2018 and 2026
Figure 11: Global Gynecology Drugs Market Value (US$ Mn) and Y-o-Y Growth, by Gynecology Cancers, 2016–2026
Figure 12: Global Gynecology Drugs Market Value (US$ Mn) and Y-o-Y Growth, by Endometriosis, 2016–2026
Figure 13: Global Gynecology Drugs Market Value (US$ Mn) and Y-o-Y Growth, by Female Infertility, 2016–2026
Figure 14: Global Gynecology Drugs Market Value (US$ Mn) and Y-o-Y Growth, by Menopausal Disorder, 2016–2026
Figure 15: Global Gynecology Drugs Market Value (US$ Mn) and Y-o-Y Growth, by Gynecology Infections, 2016–2026
Figure 16: Global Gynecology Drugs Market Value (US$ Mn) and Y-o-Y Growth, by Polycystic Ovary Syndrome, 2016–2026
Figure 17: Global Gynecology Drugs Market Value (US$ Mn) and Y-o-Y Growth, by Contraception (Birth Control), 2016–2026
Figure 18: Global Gynecology Drugs Market Value (US$ Mn) and Y-o-Y Growth, by Others, 2016–2026
Figure 19: Global Gynecology Drugs Market Attractiveness, by Indication
Figure 20: Global Gynecology Drugs Market Value Share, by Distribution Channel, 2018 and 2026
Figure 21: Global Gynecology Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2016–2026
Figure 22: Global Gynecology Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2016–2026
Figure 23: Global Gynecology Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacies, 2016–2026
Figure 24: Global Gynecology Drugs Market Attractiveness, by Distribution Channel
Figure 25: Global Gynecology Drugs Market Value Share, by Region, 2018 and 2026
Figure 26: Global Gynecology Drugs Market Attractiveness, by Region, 2018–2026
Figure 27: North America Gynecology Drugs Market Value (US$ Mn) Forecast, 2018–2026
Figure 28: North America Gynecology Drugs Market Attractiveness Analysis, by Country
Figure 29: North America Gynecology Drugs Market Value Share Analysis, by Country, 2018 and 2026
Figure 30: North America Gynecology Drugs Market Value Share Analysis, by Therapeutics, 2018 and 2026
Figure 31: North America Gynecology Drugs Market Value Share Analysis, by Indication, 2018 and 2026
Figure 32: North America Gynecology Drugs Market Value Share, by Distribution Channel, 2018 and 2026
Figure 33: North America Gynecology Drugs Market Attractiveness Analysis, by Therapeutics, 2018–2026
Figure 34: North America Gynecology Drugs Market Attractiveness Analysis, by Indication, 2018–2026
Figure 35: North America Gynecology Drugs Market Attractiveness Analysis, by Distribution Channel, 2018–2026
Figure 36: Europe Gynecology Drugs Market Value (US$ Mn) Forecast, 2018–2026
Figure 37: Europe Gynecology Drugs Market Attractiveness Analysis, by Country/Sub-region
Figure 38: Europe Gynecology Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
Figure 39: Europe Gynecology Drugs Market Value Share Analysis, by Therapeutics, 2018 and 2026
Figure 40: Europe Gynecology Drugs Market Value Share Analysis, by Indication, 2018 and 2026
Figure 41: Europe Gynecology Drugs Market Value Share, by Distribution Channel, 2018 and 2026
Figure 42: Europe Gynecology Drugs Market Attractiveness Analysis, by Therapeutics, 2018–2026
Figure 43: Europe Gynecology Drugs Market Attractiveness Analysis, by Indication, 2018–2026
Figure 44: Europe Gynecology Drugs Market Attractiveness Analysis, by Distribution Channel, 2018–2026
Figure 45: Asia Pacific Gynecology Drugs Market Value (US$ Mn) Forecast, 2018–2026
Figure 46: Asia Pacific Gynecology Drugs Market Attractiveness Analysis, by Country/Sub-region
Figure 47: Asia Pacific Gynecology Drugs Market Value Share Analysis, by Country, 2018 and 2026
Figure 48: Asia Pacific Gynecology Drugs Market Value Share Analysis, by Therapeutics, 2018 and 2026
Figure 49: Asia Pacific Gynecology Drugs Market Value Share Analysis, by Indication, 2018 and 2026
Figure 50: Asia Pacific Gynecology Drugs Market Value Share, by Distribution Channel, 2018 and 2026
Figure 51: Asia Pacific Gynecology Drugs Market Attractiveness Analysis, by Therapeutics, 2018–2026
Figure 52: Asia Pacific Gynecology Drugs Market Attractiveness Analysis, by Indication, 2018–2026
Figure 53: Asia Pacific Gynecology Drugs Market Attractiveness Analysis, by Distribution Channel, 2018–2026
Figure 54: Latin America Gynecology Drugs Market Value (US$ Mn) Forecast, 2018–2026
Figure 55: Latin America Gynecology Drugs Market Attractiveness Analysis, by Country/Sub-region
Figure 56: Latin America Gynecology Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
Figure 57: Latin America Gynecology Drugs Market Value Share Analysis, by Therapeutics, 2018 and 2026
Figure 58: Latin America Gynecology Drugs Market Value Share Analysis, by Indication, 2018 and 2026
Figure 59: Latin America Gynecology Drugs Market Value Share, by Distribution Channel, 2018 and 2026
Figure 60: Latin America Gynecology Drugs Market Attractiveness Analysis, by Therapeutics, 2018–2026
Figure 61: Latin America Gynecology Drugs Market Attractiveness Analysis, by Indication, 2018–2026
Figure 62: Latin America Gynecology Drugs Market Attractiveness Analysis, by Distribution Channel, 2018–2026
Figure 63: Middle East & Africa Gynecology Drugs Market Value (US$ Mn) Forecast, 2018–2026
Figure 64: Middle East & Africa Gynecology Drugs Market Attractiveness Analysis, by Country/Sub-region
Figure 65: Middle East & Africa Gynecology Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
Figure 66: Middle East & Africa Gynecology Drugs Market Value Share Analysis, by Therapeutics, 2018 and 2026
Figure 67: Middle East & Africa Gynecology Drugs Market Value Share Analysis, by Indication, 2018 and 2026
Figure 68: Middle East & Africa Gynecology Drugs Market Value Share, by Distribution Channel, 2018 and 2026
Figure 69: Middle East & Africa Gynecology Drugs Market Attractiveness Analysis, by Therapeutics, 2018–2026
Figure 70: Middle East & Africa Gynecology Drugs Market Attractiveness Analysis, by Indication, 2018–2026
Figure 71: Middle East & Africa Gynecology Drugs Market Attractiveness Analysis, by Distribution Channel, 2018–2026
Figure 72: Global Gynecology Drugs Market Share Analysis, by Company, 2017 (Estimated)
Complete the form below and we'll get back to you shortly.
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
